FibroGen’s anemia drug, not yet approved, is a hit among cheating cyclists

Damian Garde FibroGen's in-development treatment for anemia is still in the midst of Phase III development, but thanks to a legal loophole, the pill has made its way into the world ...

Express Scripts: Pricey PCSK9 drugs poised to ‘wreak havoc’

Carly Helfand Last week, Sanofi revealed a $ 14,600 sticker for new PCSK9 med Praluent that far exceeded the price tag analysts expected. And unsurprisingly, leading ...

Report: Parexel layoffs include up to 200 ex-GlaxoSmithKline staffers

John Carroll When GlaxoSmithKline reported last December that it was ripping into its R&D operations in Research Triangle Park, NC, and laying off 900 staffers, the pharma giant ...

With solid Q2, Sanofi CEO says M&A could be part of growth strategy

Eric Palmer Sanofi's new CEO, Olivier Brandicourt, has a new company structure he is trotting out, a new potentially hot cholesterol-lowering drug to launch and now is able to take ...

Celgene fights for sanction on patent challenger Bass

Carly Helfand Celgene is hedge fund manager Kyle Bass' latest patent target, it says–but the biotech isn't taking the news lying down. FiercePharma News

RIP: AstraZeneca clips two pipeline programs in Q2

John Carroll Every quarter AstraZeneca notes at the end of its financial report which of its new drug programs are being discarded and dropped from the pipeline. FierceBiotech News

Patrick Soon-Shiong: NantKwest is starting down the path to conquering cancer

John Carroll Patrick Soon-Shiong made several fortunes based on his understanding of cancer and drug development, most recently in today's multibillion-dollar IPO for NantKwest. ...

With new cash on its way, it’s back to buying for deal-happy Allergan, CEO says

Carly Helfand On Monday, Allergan agreed to sell off a $ 40.5 billion piece of its business, inking a pact to exit the generics space with a sale to Teva Pharmaceutical Industries. ...

UPDATED: Allergan bags NMDA depression drugs in $560M-plus Naurex buyout

John Carroll The big news in biopharma this weekend is the unconfirmed report that Allergan is looking to sell its generics business to Teva. But Allergan execs didn't let the headlines ...

Biogen gets beaten up as slowing Tecfidera sales lead it to trim forecast

Eric Palmer The speed bump that sales of Biogen's Tecfidera hit earlier this year, slowing its growth, has turned into a big old pothole and it has shaken investors pretty hard ...

Sanofi and Regeneron line up for second place in EU cardio race

Damian Garde Sanofi and Regeneron may be on pace to win the first U.S. approval for a new type of cholesterol treatment, but the pair trails rival Amgen in Europe in a race to make ...

Novartis’ newly acquired melanoma combo wins EU recommendation

Carly Helfand Novartis' recently acquired melanoma duo, Tafinlar and Mekinist, has won a recommendation from the European Medicines Agency's Committee for Medicinal Products ...
Page 1 of 512345
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS